Market Summary
Recombinant DNA Technology Market Overview
As per MRFR analysis, the Recombinant DNA Technology Market Size was estimated at 774.12 (USD Billion) in 2024. The Recombinant DNA Technology Market Industry is expected to grow from 813.61 (USD Billion) in 2025 to 1,273.26 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.10% during the forecast period (2025 - 2034).Advancements in the treatment of deadly human illnesses such as diabetes, infectious infections, and cancer are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Recombinant DNA technology (RDT) enhances health conditions by creating novel medications and vaccines. Additionally, novel therapeutic modalities, monitoring tools, and diagnostic kits are being developed to enhance treatment tactics. Furthermore, by making it possible to create a recombinant DNA molecule, the progressive improvement of rDNA techniques has opened new avenues for advancing biopharmaceutical research. This technology is anticipated to be adopted by the presence of a strong biopharmaceutical pipeline, particularly the pipeline for recombinant proteins. Due to this, it is now used in a wide range of conventional and non-traditional applications. Without the aid of human donors, recombinant medicines and treatments have been produced with great success over the past few years.
Recombinant DNA technology (RDT) enhances health conditions by creating novel medications and vaccines. Additionally, novel therapeutic modalities, monitoring tools, and diagnostic kits are being developed to enhance treatment tactics. Furthermore, by making it possible to create a recombinant DNA molecule, the progressive improvement of rDNA techniques has opened new avenues for advancing biopharmaceutical research. The widespread use of this technology is anticipated to be fueled by the presence of a strong biopharmaceutical pipeline, particularly the pipeline for recombinant proteins. Due to this, it is now used in a wide range of conventional and non-traditional applications. Without the aid of human donors, recombinant medicines and treatments have been produced with great success over the past few years.
Recombinant DNA technology is also employed for illness diagnosis by creating radioactive probes and diagnostic kits. The technology offers cross-disciplinary uses and the ability to address significant facets of life, such as boosting food supplies and promoting health. Increased product output, higher virus, insect resistance, and increased adaptation for longer survival benefit genetically engineered plants. Recombinant DNA technology can make antibiotics, hormones like insulin, enzymes, interferons, and many other medications. Recombinant DNA technology entails isolating the desired gene and inserting it into a vector DNA to produce the desired gene on a wide scale. The expansion of GM crop acreage globally is evidence of this technology's success in the food and agricultural industries. This has sparked its use in other unconventional applications, including the creation of biofuel and biopesticides to solve environmental problems.
Scientists at the Indian Institute of Technology (IIT), Guwahati, have come up with a 'Recombinant Protein Toolbox' made up of six distinct proteins that can be utilized to transform cardiomyocytes, or heart cells, from healthy skin cells or any other somatic cells from an adult human body. The injured cardiac tissues can be rebuilt utilizing the heart cells produced using this toolbox, which can perform the same activity as the original heart cells. Significantly, this toolkit can make it easier for lab-grown autologous heart cells to be produced.
A Collaboration was announced by Core Biogenesis, a biotech company, and Nucleus Biologics, which provides custom cell growth media, tools and technology for cell and gene therapy, on January 24th, 2024, for manufacturing cost-effective, sustainable recombinant proteins.In China in December 2023, the international beauty brand L’Oreal unveiled the recombined Collagen Royal Anti-Aging Face Cream. This was a huge moment for L’Oreal Paris skincare because it marked the first-ever inclusion of recombinant collagen into its product, thereby signifying a big stride towards commercializing this product from the recombinant collagen industry.NewBiologix SA emerged as a stealthy tech revolutionizer in May 2023 in Switzerland and developed a breakthrough proprietary platform for modern engineered cell lines used to create cell and gene therapies. The company is developing a DNA-based platform to address major challenges related to the production of recombinant adeno-associated virus vectors aimed at making modern therapy medicinal products.VBI Vaccines Inc. launched PreHevBrio (Recombinant Hepatitis B Vaccine) in March 2022 in the USA as one way of avoiding viral infection due to all known subtypes of Hepatitis B Virus among persons aged above 18 years.The Institute for Molecular Medicine (IMM), PharamJet’s partner, also reported an award from the National Institutes of Health (NIH)’s National Institute on Aging (NIA). It included a $12m National Institute on Aging grant provided by PharmaJet’s collaborator. This funding has enabled the undertaking of clinical trials for beta-amyloid vaccines, which are based on DNA as well as recombinant proteins for preventing Alzheimer's disease across several nations. These studies have been instrumental to market development.In March 2022, VBI Vaccines Inc. introduced PreHevbrio (Recombinant Hepatitis B Vaccine) into United States markets specifically designed for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults aged 18 years and above.
Recombinant DNA Technology Market Trends
- Growing technological advancements is driving the market growth
Market CAGR for recombinant DNA technology is being driven by the rising technological advancements. The boom promotes the development of new goods and technical developments. The Recombinant DNA Technology Market is also expanding due to increased R&D activities for treating critical illnesses like cancer, diabetes, and other immunodeficiency disorders. The marriage of technology and medicine allows for treating illnesses by replacing defective or diseased genes in a patient's body with newer, healthier ones. Furthermore, gene therapy has been used to treat genetic diseases due to advancements in recombinant technology. This will help the Recombinant DNA Technology Market grow over the forecast period. Furthermore, the recombinant DNA technology market allows researchers to treat diabetes by producing human insulin as the host cell in bacteria. Because bacteria manufacture it, this medicine is more effective than traditional drugs. As a result, these improvements are projected to aid market growth in the coming years. A good example of this achievement is the commercial success of genetically engineered insulin for diabetic treatment. Biotech and pharmaceutical industries are collaborating to better understand the possibilities of rDNA methods in a variety of disease therapy scenarios. This is largely to combat the rising burden of chronic diseases and to meet the increasing demand for treatments.
Furthermore, the progressive improvement of rDNA methods has opened up new avenues for biopharmaceutical research by allowing the synthesis of a recombinant DNA molecule. The availability of a robust biopharmaceuticals pipeline, particularly a pipeline of recombinant proteins, is likely to boost the adoption of this technology. The emergence of this field is primarily attributed to the development of recombinant products employing rDNA methods in conjunction with ZFN, CRISPR/Cas9 nuclease and TALEN allowing simple and precise genome editing with no organismal limitations. Dozens of review studies conducted by researchers demonstrate the effectiveness of rDNA technology. Thus, driving the Recombinant DNA Technology market revenue.
Recombinant DNA Technology Market Segment Insights
Recombinant DNA Technology Product Insights
The Recombinant DNA Technology market segmentation, based on product, includes medical and non-medical. The medical segment dominated the market, accounting for 65% of market revenue. rDNA technology has transformed the medical world and greatly influences clinical care. It has aided illness therapy by allowing for the insertion of fresh genes instead of damaged or sick genes. The medical sector is subdivided into medicinal drugs, recombinant proteins, and vaccines.
Recombinant DNA Technology Component Insights
Based on components, the Recombinant DNA Technology market segmentation includes expression systems and cloning vectors. The expression system segment dominated the market. The majority was obtained by expression techniques, owing to continual advancements in effective protein expression and large-scale protein separation. Expression systems from mammals, bacteria, insects, and yeast are often used. The development of cell lines such as HEK293 and Chinese Hamster Ovarian (CHO) has greatly increased the market share of mammalian expression systems.
Recombinant DNA Technology Application Insights
The Recombinant DNA Technology market segmentation is based on food & agriculture and health & disease. The food & agriculture segment dominated the market. This high proportion can be attributable to various recombinant products for human illness treatment, including vaccines, medicines, and enzyme replacements. Furthermore, the expanded usage of this technology for animal illness treatment has fueled the segment's growth.
Recombinant DNA Technology End User Insights
Based on End Users, the Recombinant DNA Technology market segmentation includes biotechnology companies and pharmaceuticals. The biotechnology companies generated the most income (70.4%). These firms are implementing this technology to maintain their medication output in terms of quality. The application of this technology in the production of various pharmaceuticals is predicted to have a significant influence in the future. Various corporations have increased their investments to give better alternatives to customers and deliver better drugs for therapeutic purposes.
Figure 1: Recombinant DNA Technology Market, by End User, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Depending on the product, medical and non-medical products are included in the market segmentation for recombinant DNA technology. Expression systems and cloning vectors are part of the Recombinant DNA technology market segmentation based on components. Food & agriculture and health & disease are the two main segments of the recombinant DNA technology market. Biotechnology firms and pharmaceuticals are included in the recombinant DNA technology market segmentation based on End Users.
Recombinant DNA Technology Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Recombinant DNA Technology market area will dominate this market; with the rising frequency of chronic illnesses, there is an increase in recombinant DNA technologies for disease prevention, treatment, and management. Because of many biopharmaceutical manufacturing businesses, the United States has the largest market share.
Further, the major countries studied in the market report are The US, India, Australia, Canada, German, France, the UK, Italy, Spain, China, Japan, South Korea, and Brazil.
Figure 2: RECOMBINANT DNA TECHNOLOGY MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe has the second-largest market share for Recombinant DNA Technology. The presence of robust regulatory organizations to oversee the myriad ethical and scientific problems linked with technology use has spurred regional advancement. Furthermore, the German Recombinant DNA Technology market dominated, while the UK Recombinant DNA Technology market grew fastest in Europe.
From 2023 to 2032, the Asia-Pacific Recombinant DNA Technology Market will develop at the quickest CAGR. Because of the availability of competent and inexpensive laborers, some corporations are relocating their production base to the Asia-Pacific area. Recombinant and genetically modified items for human health, food, and agriculture are in high demand. Furthermore, China's Recombinant DNA Technology market had the highest market share, whereas India's Recombinant DNA Technology market was the Asia-Pacific region's fastest growing.
Recombinant DNA Technology Key Market Players & Competitive Insights
Leading market companies are extensively spending R&D on increasing their product lines, which will help the Recombinant DNA Technology market grow even more. Important market developments include new product releases, acquisitions and mergers, contractual agreements, greater investments, and collaboration with other organizations. The Recombinant DNA Technology industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.
Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Recombinant DNA Technology industry to serve clients and expand the market sector. The Recombinant DNA Technology industry has provided some of the most important benefits recently. PharmaJet, Corteva Inc., and other major companies in the Recombinant DNA Technology market are aiming to enhance market demand by investing in research and development activities.
PharmaJet is a commercial-stage MedTech company with distribution in the United States and abroad. Needle-free Systems from PharmaJet deliver enhanced vaccination efficacy, a better patient and carer experience, and a proven road to commercialization. They are also secure, quick, and simple to use.In May 2016, the PharmaJet Tropis intradermal injection device got CE Mark approval. Tropis acquired WHO Pre-Qualification (PQS) in June 2018 after establishing an FDA Master File as a prelude to 510(k). The unique PharmaJet Stratis Needle-Free Injector has FDA 510(k) marketing approval, CE Mark, and WHO PQS certification for intramuscular or subcutaneous administration of drugs and vaccines. In May 2022, The National Institute on Ageing (NIA) branch of the National Institutes of Health (NIH) awarded USD 12 million to PharmaJet's partner, the Institute for Molecular Medicine (IMM). The award funds clinical studies of beta-amyloid vaccinations based on DNA and recombinant proteins for Alzheimer's disease (AD) prevention. Such research investigations are moving the industry forward.
Corteva Agriscience blends industry-leading ideas, high-touch customer interaction, and operational execution to deliver profitably on the world's most critical agricultural issues. Corteva gains market preference through its distinct distribution approach and its well-balanced and globally broad portfolio of seed, crop protection, and digital goods and services. With some of the most recognized brands in agriculture and a technology pipeline well-positioned to drive growth, the company is committed to maximizing farmer productivity while working with stakeholders across the food system to fulfill its promise of enriching the lives of those who produce and those who consume, ensuring progress for future generations. In August 2021, Corteva Inc. introduced a genetically engineered Conkesta E3 soybean seed in the Brazilian market. The European Union Commission has permitted grain generated from Conkesta E3 soybean seeds cultivated in Brazil to be sold to the European market for food and feed usage.
Key Companies in the Recombinant DNA Technology market include
-
Amgen Inc. (U.S.)
-
F. Hoffmann-La Roche Ltd (Switzerland)
-
Profacgen (U.S.)
-
Novartis AG (Switzerland)
-
Novo Nordisk A/S (Denmark)
-
Genscript Biotech (U.S.)
-
Pfizer Inc. (U.S.)
-
Sanofi S.A. (France)
-
Eli Lilly and Company (U.S.)
-
Biogen Inc. (U.S.).
Recombinant DNA Technology Industry Developments
March 2022:PreHevbrio (Recombinant Hepatitis B Vaccine) was introduced in the United States by VBI Vaccines Inc. to prevent viral infection caused by all known subtypes of hepatitis B virus (HBV) in people aged 18 and older.
February 2022:VBI Vaccines Inc. received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for its 3-antigen hepatitis B (HBV) vaccine, PreHevbri, for active immunization against infection resulting from all known subtypes of the hepatitis B virus in adults.
Recombinant DNA Technology Market Segmentation
Recombinant DNA Technology Product Outlook
-
Medical
-
Non-Medical
Recombinant DNA Technology Component Outlook
-
Expression System
-
Cloning Vector
Recombinant DNA Technology Application Outlook
-
Food & Agriculture
-
Health & Disease
Recombinant DNA Technology End User Outlook
-
Biotechnology Companies
-
Pharmaceuticals
Recombinant DNA Technology Regional Outlook
-
North America
-
-
US
-
Canada
-
-
Europe
-
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
-
Market Size & Forecast
| Report Attribute/Metric | Details |
|
Market Size 2024 |
774.12 (USD Billion) |
|
Market Size 2025 |
813.61 (USD Billion) |
|
Market Size 2034 |
1,273.26 (USD Billion) |
|
Compound Annual Growth Rate (CAGR) |
5.10 % (2025 - 2034) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Base Year |
2024 |
|
Market Forecast Period |
2025 - 2034 |
|
Historical Data |
2020 - 2024 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Amgen Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Profacgen (U.S.), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Genscript Biotech (U.S.), Pfizer Inc. (U.S.), Sanofi S.A. (France), Eli Lilly and Company (U.S.), and Biogen Inc. (U.S.), |
| Key Market Opportunities | Product development |
| Key Market Dynamics | Increased R&D initiatives and strategic collaborations among industry participants |
Major Players
Market Segmentation
Recombinant DNA Technology Product Outlook (USD Billion, 2018-2032)
-
Medical
-
Non-Medical
Recombinant DNA Technology Component Outlook (USD Billion, 2018-2032)
-
Expression System
-
Cloning Vector
Recombinant DNA Technology Application Outlook (USD Billion, 2018-2032)
-
Food & Agriculture
-
Health & Disease
Recombinant DNA Technology End User Outlook (USD Billion, 2018-2032)
-
Biotechnology Companies
-
Pharmaceuticals
Recombinant DNA Technology Regional Outlook (USD Billion, 2018-2032)
-
North America Outlook (USD Billion, 2018-2032)
-
North America Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
North America Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
North America Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
North America Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
US Outlook (USD Billion, 2018-2032)
-
US Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
US Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
US Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
US Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
CANADA Outlook (USD Billion, 2018-2032)
-
CANADA Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
CANADA Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
CANADA Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
CANADA Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
-
Europe Outlook (USD Billion, 2018-2032)
-
Europe Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
Europe Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
Europe Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
Europe Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
Germany Outlook (USD Billion, 2018-2032)
-
Germany Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
Germany Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
Germany Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
Germany Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
France Outlook (USD Billion, 2018-2032)
-
France Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
France Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
France Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
France Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
UK Outlook (USD Billion, 2018-2032)
-
UK Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
UK Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
UK Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
UK Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
ITALY Outlook (USD Billion, 2018-2032)
-
ITALY Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
ITALY Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
ITALY Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
ITALY Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
SPAIN Outlook (USD Billion, 2018-2032)
-
Spain Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
Spain Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
Spain Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
Spain Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
Rest Of Europe Outlook (USD Billion, 2018-2032)
-
Rest Of Europe Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
Rest Of Europe Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
Rest Of Europe Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
Rest Of Europe Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
-
Asia-Pacific Outlook (USD Billion, 2018-2032)
-
Asia-Pacific Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
Asia-Pacific Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
Asia-Pacific Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
Asia-Pacific Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
China Outlook (USD Billion, 2018-2032)
-
China Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
China Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
China Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
China Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
Japan Outlook (USD Billion, 2018-2032)
-
Japan Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
Japan Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
Japan Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
Japan Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
India Outlook (USD Billion, 2018-2032)
-
India Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
India Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
India Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
India Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
Australia Outlook (USD Billion, 2018-2032)
-
Australia Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
Australia Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
Australia Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
Australia Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)
-
Rest of Asia-Pacific Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
Rest of Asia-Pacific Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
Rest of Asia-Pacific Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
Rest of Asia-Pacific Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
-
Rest of the World Outlook (USD Billion, 2018-2032)
-
Rest of the World Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
Rest of the World Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
Rest of the World Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
Rest of the World Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
Middle East Outlook (USD Billion, 2018-2032)
-
Middle East Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
Middle East Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
Middle East Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
Middle East Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
Africa Outlook (USD Billion, 2018-2032)
-
Africa Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
Africa Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
Africa Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
Africa Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
Latin America Outlook (USD Billion, 2018-2032)
-
Latin America Recombinant DNA Technology by Product
-
Medical
-
Non-Medical
-
-
Latin America Recombinant DNA Technology by Component
-
Expression System
-
Cloning Vector
-
-
Latin America Recombinant DNA Technology by Application
-
Food & Agriculture
-
Health & Disease
-
-
Latin America Recombinant DNA Technology by End User
-
Biotechnology Companies
-
Pharmaceuticals
-
-
Leave a Comment